- Canadian findings showed that 52 percent (45/87) of study
participants with Crohn's disease and 43 percent (33/76) of study
participants with ulcerative colitis suffered from suboptimally
controlled disease.1
- People living with suboptimally controlled IBD showed higher
daily disease burden, lower quality of life and lower work
productivity compared to people who had achieved complete disease
control.1
- Patients and clinicians underestimated the extent of
suboptimally controlled disease, indicating greater need for
education on appropriate treatment targets and recognition of
quality-of-life indicators.1
MONTREAL, May 23, 2024
/CNW/ - A new Canadian study of people living with IBD found
that approximately half of study participants suffered from
suboptimally controlled disease, which can be connected to lower
quality of life.1 The study, published in the scientific
journal Digestive Diseases and Sciences, found that 52
percent (45/87)* of people living with Crohn's disease had
suboptimally controlled disease, while 43 percent (33/76)* of
people living with ulcerative colitis had sub-optimally controlled
disease.1
The IBD PODCAST study (Proportion Of inadequate Disease Control
And Strategy of Treatment in IBD), which was initiated and
supported by AbbVie, assessed in a real clinical practice whether
patients with IBD were achieving disease control as measured by the
STRIDE-II guideline recommendations**, and the impact on their
quality of life.2 The Canadian PODCAST study was part of
a broader analysis that included over 2,000 patients across 10
countries.2
Study findings showed that approximately half of patients with
IBD had suboptimally controlled disease, mainly with respect to
longer-term treatment goals of achieving a good quality of
life.1
People with suboptimally controlled disease had numerically
higher work productivity loss and activity impairment
scores.1
The Canadian findings also highlighted an important discordance
between physician and patient perceptions of disease control, and
disease control based on STRIDE-II recommendations. Both patients
and physicians tended to under report patients' suboptimally
controlled disease. Between 80 to 85 per cent of patients with
objectively measured suboptimally controlled disease had either a
patient or physician report that the patient's disease was
optimally controlled.1
"The IBD PODCAST study shows that there is a disconnect between
patients and physicians thinking the patient is doing well, and
whether the patient's disease is truly under control based on
objective measures. The reality is that about half of people are
not doing as well as they could be doing.
Ensuring physicians are aware of these findings and implementing
STRIDE-II recommendations should make a huge difference in the IBD
community," explains Dr. Jesse
Siffledeen, MD, FRCPC, Division of Gastroenterology,
Department of Medicine, University of
Alberta, and lead author of the IBD-PODCAST Canada Trial
publication.
Inflammatory bowel disease (IBD) describes a group of
conditions—the two main forms being Crohn's disease and ulcerative
colitis—that cause inflammation of the gastrointestinal tract and
disrupt the body's ability to digest food, absorb nutrition and
eliminate waste in a healthy way.[3] Canada has one of the highest rates of IBD in
the world, with more than 300,000 Canadians currently living with
the disease.[4] People living with IBD can experience severe
abdominal pain, fatigue, diarrhea and frequent bowel
urgency.3
"Through regular surveys of the Canadian IBD community, we know
that Crohn's disease and ulcerative colitis can have a negative
impact on people's quality of life," says Kate Lee, Vice President, Research and Patient
Program, Crohn's and Colitis Canada. "We believe it is important
that patients are able to advocate for themselves and have an open,
honest dialogue with their health care team, to work together to
better assess the disease impact and align on appropriate long-term
goals."
"For more than two decades, AbbVie has worked hand-in-hand with
the IBD research community to advance patient-centered clinical
practice, and the IBD PODCAST study is one example of our
commitment in gastroenterology," says Rami Fayed, Vice President
and General Manager, AbbVie Canada. "We are proud of our legacy
supporting important research initiatives like this one, as they
help to elevate the standard of care and ultimately make a
remarkable impact on people's lives."
* Confidence interval: 45/87 (51.7%; 95% CI: 40.8%, 62.6%) of
study participants with CD and 33/76 (43.3%; 95% CI: 32.1%, 55.3%)
of study participants with UC had sub-optimally controlled disease
based on the STRIDE-II recommendations.1
** The STRIDE-II recommendations (Selecting Therapeutic
TaRgets in Inflammatory Bowel DiseasE II) were published in 2021 by
the International Organization for the Study of IBD, to assist
clinicians with helping their patients attain short- and
longer-term treatment goals.[5] Short-term goals include reducing
or eliminating symptoms, while longer-term goals include absence of
inflammation or lesions in the colon (mucosal healing), a normal
quality of life, and absence of disability.4
About the IBD PODCAST
study1,2
IBD PODCAST (Proportion Of inadequate Disease Control And
Strategy of Treatment in IBD), initiated and supported by AbbVie,
is the first study to evaluate the implementation of the STRIDE-II
recommendations in daily clinical practice. It is a
non-interventional, multicentre, observational study which included
both cross-sectional and retrospective assessments. The study
evaluated 2,185 patients (1,108 with Crohn's disease and 1,077 with
ulcerative colitis) from ten different countries: Austria, Belgium, Canada, Germany, Greece, Italy, Portugal, Spain, Turkey
and the United Kingdom.
In Canada, participants
included 163 patients enrolled from 10 sites across the country.
Canadian results were consistent with results seen across all
participating countries in the international study.
The primary endpoints were the proportion of patients with red
flags indicative of suboptimal disease control based on the
STRIDE-II recommendations, and differences in the Short
Inflammatory Bowel Disease Questionnaire (SIBDQ) scores between
patients with suboptimal and optimal disease control.
For more information on the IBD-PODCAST Canada study including
study limitations, please find the manuscript here.
About AbbVie in
Gastroenterology
AbbVie has focused on improving care in gastroenterology for
more than 10 years. With a robust clinical trial program in
inflammatory bowel disease (IBD), we are committed to cutting-edge
research to drive new discoveries and developments in Crohn's
disease and ulcerative colitis. By
innovating, learning and adapting, AbbVie aspires to eliminate
the burden of IBD and make a positive long-term impact in the lives
of people with IBD.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.ca. Follow AbbVie
Canada on X (Twitter), on Instagram, or find us on
LinkedIn.
References
___________________________________
|
1
Siffledeen, J., Singh, S., Shulman, S.M. et al. Effect
of Suboptimal Disease Control on Patient Quality of Life:
Real-World Data from the Observational IBD-PODCAST Canada
Trial. Dig Dis Sci 69, 1636–1648 (2024).
https://doi.org/10.1007/s10620-024-08313-z Accessed May
1, 2024.
|
2
D'Amico, F., et al. Proportion of inflammatory bowel disease
patients with suboptimal disease control in daily clinical practice
– Real-world evidence from the inflammatory bowel diseases podcast
study. United European Gastroenterology Journal. Available
at: https://onlinelibrary.wiley.com/doi/10.1002/ueg2.12572 Accessed
May 14, 2024.
|
3
Crohn's and Colitis Canada. What are Crohn's and
Colitis. https://crohnsandcolitis.ca/About-Crohn-s-Colitis/What-are-Crohns-and-Colitis
Accessed May 1, 2024.
|
4
Crohn's and Colitis Canada. 2023 Impact of IBD
Report. https://crohnsandcolitis.ca/About-Us/Resources-Publications/Impact-of-IBD-Report
Accessed May 1, 2024.
|
5
Turner, D., et al. STRIDE-II: An Update on the Selecting
Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
Initiative of the International Organization for the Study of IBD
(IOIBD): Determining Therapeutic Goals for Treat-to-Target
strategies in IBD. Gastroenterology Journal. Accessed
May 1, 2024: https://pubmed.ncbi.nlm.nih.gov/33359090/
|
SOURCE AbbVie Canada